(0.52%) 5 072.50 points
(0.40%) 38 222 points
(0.65%) 17 552 points
(0.65%) $79.51
(1.19%) $1.955
(0.68%) $2 326.70
(0.25%) $26.82
(1.48%) $969.00
(0.00%) $0.933
(-0.03%) $11.03
(-0.08%) $0.798
(-0.26%) $93.02
0.05% £ 3 866.00
Live Chart Being Loaded With Signals
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development...
Stats | |
---|---|
Объем за сегодня | 192 108 |
Средний объем | 1.36M |
Рыночная капитализация | 4.40B |
EPS | £0 ( 2024-02-25 ) |
Last Dividend | £12.50 ( 2023-03-09 ) |
Next Dividend | £0 ( N/A ) |
P/E | -154.64 |
ATR14 | £15.19 (0.39%) |
Объем Корреляция
Dechra Pharmaceuticals Корреляция
10 Самые положительные корреляции | |
---|---|
BUR.L | 0.808 |
10 Самые отрицательные корреляции | |
---|---|
DMGT.L | -0.834 |
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Dechra Pharmaceuticals Корреляция - Валюта/Сырье
Dechra Pharmaceuticals Финансовые показатели
Annual | 2022 |
Выручка: | £761.50M |
Валовая прибыль: | £426.30M (55.98 %) |
EPS: | £-0.240 |
FY | 2022 |
Выручка: | £761.50M |
Валовая прибыль: | £426.30M (55.98 %) |
EPS: | £-0.240 |
FY | 2022 |
Выручка: | £681.80M |
Валовая прибыль: | £384.80M (56.44 %) |
EPS: | £0.540 |
FY | 2021 |
Выручка: | £608.00M |
Валовая прибыль: | £345.90M (56.89 %) |
EPS: | £0.538 |
Financial Reports:
No articles found.
Dechra Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£0 (N/A) |
£32.89 (N/A) |
£12.50 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | £1.133 | 2001-03-07 |
Last Dividend | £12.50 | 2023-03-09 |
Next Dividend | £0 | N/A |
Payout Date | 2023-04-13 | |
Next Payout Date | N/A | |
# dividends | 45 | -- |
Total Paid Out | £356.25 | -- |
Avg. Dividend % Per Year | 0.54% | -- |
Score | 2.05 | -- |
Div. Sustainability Score | 3.80 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 1.261 | -- |
Year | Amount | Yield |
---|---|---|
2001 | £0 | 0.00% |
2002 | £0 | 0.00% |
2003 | £0 | 0.00% |
2004 | £0 | 0.00% |
2005 | £0 | 0.00% |
2006 | £0 | 0.00% |
2007 | £0 | 0.00% |
2008 | £0 | 0.00% |
2009 | £0 | 0.00% |
2010 | £0 | 0.00% |
2011 | £0 | 0.00% |
2012 | £0 | 0.00% |
2013 | £0 | 0.00% |
2014 | £0 | 0.00% |
2015 | £0 | 0.00% |
2016 | £0 | 0.00% |
2017 | £0 | 0.00% |
2018 | £25.50 | 0.92% |
2019 | £31.60 | 1.51% |
2020 | £34.29 | 1.17% |
2021 | £40.50 | 1.14% |
2022 | £44.89 | 0.94% |
2023 | £12.50 | 0.48% |
2024 | £0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
DEC.L | Dividend Knight | 2023-08-31 | Quarterly | 8 | 2.83% | |
SFE.L | No Dividend Player | 2023-05-04 | Annually | 11 | 0.26% | |
ICP.L | Dividend King | 2023-06-15 | Semi-Annually | 31 | 2.60% | |
BLND.L | Dividend Knight | 2023-06-22 | Semi-Annually | 32 | 2.45% | |
WYN.L | Dividend Knight | 2023-09-28 | Semi-Annually | 20 | 1.95% | |
NVT.L | Dividend Knight | 2023-07-20 | Semi-Annually | 29 | 4.15% | |
EMR.L | Dividend Junior | 2023-05-25 | Annually | 20 | 1.50% | |
SQZ.L | Dividend Knight | 2023-10-26 | Annually | 5 | 3.33% | |
JEL.L | Dividend King | 2023-06-01 | Semi-Annually | 28 | 2.22% | |
BWY.L | Dividend Knight | 2023-05-25 | Annually | 33 | 2.07% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0366 | 1.500 | -0.733 | -1.099 | [0 - 0.5] |
returnOnAssetsTTM | -0.0178 | 1.200 | -0.593 | -0.711 | [0 - 0.3] |
returnOnEquityTTM | -0.0349 | 1.500 | -1.499 | -2.25 | [0.1 - 1] |
payoutRatioTTM | -1.853 | -1.000 | -10.00 | 10.00 | [0 - 1] |
currentRatioTTM | 2.85 | 0.800 | 0.735 | 0.588 | [1 - 3] |
quickRatioTTM | 1.333 | 0.800 | 6.87 | 5.49 | [0.8 - 2.5] |
cashRatioTTM | 0.454 | 1.500 | 8.59 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.321 | -1.500 | 4.64 | -6.96 | [0 - 0.6] |
interestCoverageTTM | 0.767 | 1.000 | -0.827 | -0.827 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.559 | 2.00 | 9.81 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.358 | 2.00 | 9.82 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.668 | -1.500 | 7.33 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.564 | 1.000 | 3.93 | 3.93 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0225 | 1.000 | -1.551 | -1.551 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.126 | 1.000 | -0.411 | -0.411 | [0.2 - 2] |
assetTurnoverTTM | 0.485 | 0.800 | -0.0986 | -0.0788 | [0.5 - 2] |
Total Score | 3.80 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -157.77 | 1.000 | -10.00 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0349 | 2.50 | -0.964 | -2.25 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.358 | 2.00 | 9.88 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.559 | 2.00 | 9.81 | 10.00 | [0 - 30] |
payoutRatioTTM | -1.853 | 1.500 | -10.00 | 10.00 | [0 - 1] |
pegRatioTTM | -1 577.69 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0835 | 1.000 | -0.412 | 0 | [0.1 - 0.5] |
Total Score | -1.282 |
Dechra Pharmaceuticals
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа